|
Study of Gelonin Purging of Autologous Stem Cells for Transplantation Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for qualified medical advice, visits or professional assistance by using a real mD. We are not docs. Always confer with your physician about Study of Gelonin Purging of Autologous Stem Cells for Transplantation conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Study of Gelonin Purging of Autologous Stem Cells for Transplantation Clinical research trials and Study of Gelonin Purging of Autologous Stem Cells for Transplantation health trials occur in many of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectivity of new does drugs. The intent of the studies / undertakings is to resolve particular human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to detect remedies for all sorts of conditions, including Study of Gelonin Purging of Autologous Stem Cells for Transplantation. Study of Gelonin Purging of Autologous Stem Cells for Transplantation Clinical Trials and other clinical trials permit volunteers to obtain healthcare treatment alternatives before they are available to the masses. Most times the participants undergo professional assistance for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Study of Gelonin Purging of Autologous Stem Cells for Transplantation clinical trial. Test subjects typically receive the most expert healthcare available for their Study of Gelonin Purging of Autologous Stem Cells for Transplantation condition. Dangers are a reality, however, and may include more or frequent mD visits, healthcare dangers (perhaps life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Study of Gelonin Purging of Autologous Stem Cells for Transplantation  Study of Gelonin Purging of Autologous Stem Cells for Transplantation
Study of Gelonin Purging of Autologous Stem Cells for Transplantation
For Condition: Acute Myelogenous Leukemia,Myelodysplastic Syndrome
Status: Suspended
Sponsor(s): M.D. Anderson Cancer Center ,
Synopsis: Patients with Acute Myelogenous Leukemia or Myelodysplastic are able to achieve a complete remission but fail to achieve a prolonged disease-free survival. High dose chemotherapy and autologous bone marrow transplantation has been shown to be effective in this group of patients but hematopoietic recovery is slow, and infectious or bleeding complications are common. The delay in hematopoietic recover is accentuated by the use of purging techniques. This is a novel purging approach for autologous stem cell transplantation in patients with Acute Myelogenous Leukemia or Myelodysplastic syndrome to allow for rapid engraftment with a lower relapse rate therefore improving the therapeutic outcomes
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: - Patients with AML, RAEB-t, RAEB, or CMML who are in first remission and have poor prognosis cytogenetic abnormalities (i.e: deletions of chromosome 5, 7, 20; trisomy 8, t9,22,11q23 abnormalities or complex karyotypes).* - Patients with AML, RAEB-t, RAEB, or CMML who are in second or subsequent remission. - Remission is defined as ANC>1.5 x 109/Lt; Platelet count >100 x 109/Lt, and red cell transfusion independence. - Male or female who have provided written informed consent. - Tumor cells must be > 80 % CD-33 positive by flow cytometry. - For women of childbearing potential (i.e., exclude post-menopausal women, women who have been surgically sterilized), adequate birth control methods must be used. Acceptable birth control methods are limited to oral contraceptives, implants, diaphragm, IUD or spermicide used with a condom) - No chemotherapy for the two weeks prior to entering the study. - No evidence of residual toxic effects from prior chemotherapy. - Patients with proven bacterial infection are not eligible until resolution of the infection (patient afebrile, not on steroids). Patients with active fungal infections are eligible only if evidence of response to antifungal medications is documented and they do not have fever exceeding 38C. - Must have at least 5 x 106 CD34+ peripheral blood stem cells collected. - All patients who have had less than 7 x 106 CD34+ cells/kg collected, should have a bone marrow harvest to serve as back-up. - A minimum of 1 x 106 CD34+ cells/kg of unpurged bone marrow or 2 x 106 CD34+ cells/kg of unpurged peripheral blood need to be stored as backup to be eligible for this protocol. - Patients must have bilirubin less than 2.0, transaminases less than 4 x upper limit of normal. - Pulmonary function tests >50% predicted for DLCO, FVC and FEV1 - No active uncontrolled infection - No active CNS disease - No uncontrolled arrythmias - Zubrod Performance Status less than or equal to 2
Total Enrollment: 24
Location and Contact Information:
MD Anderson Cancer Center
Houston, Texas, 77030
United States
Additional Information:
Study ID Numbers: ID02-060;
Study Start Date: July 2002
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00043810
Other Myelodysplastic Syndrome Studies:
1. Megadose CD34 Selected Progenitor Cells for Transplantation in Patients with Advanced Hematological Malignant Diseases
2. Study of Gelonin Purging of Autologous Stem Cells for Transplantation
3. Phase II Study of CLOFARABINE in Adult Patients with Refractory or Relapsed Acute Myelogenous Leukemia
4. Therapy of Relapsed AML with Chemotherapy and Dendritic Cell Activated Lymphocytes
5. Dose-finding, open-label study in patients with Acute Myelogenous Leukemia after they receive a transplantation
Related Studies:
Other Myelodysplastic Syndrome Clinical Trials
Other Texas Clinical Trials
Other Houston Clinical Trials
Study of Gelonin Purging of Autologous Stem Cells for Transplantation
|
|
|
|
|
|
|
|
